Business Overview: Avenue Therapeutics, Inc. (NASDAQ: ATXI)

---

Executive Summary

Avenue Therapeutics, Inc., headquartered in New York and majority-owned by Fortress Biotech, is a clinical-stage specialty pharmaceutical company focused on developing an intravenous (IV) formulation of tramadol for the management of moderate-to-severe acute post-operative pain in adults in medically supervised settings such as hospitals. Avenue's strategy leverages the well-established clinical and safety profile of tramadol (a widely used oral analgesic) delivered via a proprietary IV formulation intended to give hospital clinicians a rapid-onset, non-oral option for acute post-surgical pain management. As a clinical/regulatory-stage company, Avenue generates no material product revenue today.

---

1. Core Business Model & How They Work

Avenue's model is a specialty pharma "505(b)(2)"-style development strategy: leveraging an already-characterized active pharmaceutical ingredient (tramadol) in a novel formulation and route of administration (IV) to pursue a more capital-efficient regulatory pathway than developing an entirely new molecular entity.

[ Leverage Known Tramadol Safety/Efficacy Profile ] ➡️ [ Develop Proprietary IV Formulation ] ➡️ [ Clinical Trials in Post-Operative Pain Settings ] ➡️ [ FDA Regulatory Review ] ➡️ [ Hospital/Institutional Commercialization or Partnership ]

Key Operational Drivers

1. Leveraging an Established Molecule: By building on tramadol's decades-long clinical use profile as an oral analgesic, Avenue aims to reduce some of the clinical and safety uncertainty inherent in developing a wholly novel pain therapeutic.
2. Hospital-Focused Acute Pain Niche: IV tramadol targets a specific clinical need — rapid, injectable post-operative pain control for patients who cannot take oral medication immediately after surgery — positioning it within hospital pharmacy and anesthesiology purchasing decisions rather than broad retail pharmacy channels.
3. Fortress Biotech Affiliation: As part of the broader Fortress Biotech family of majority-owned subsidiary companies, Avenue benefits from shared drug development, regulatory, and capital markets expertise and infrastructure common across the Fortress portfolio.
4. Regulatory Pathway Dependency: The company's near-term value is entirely tied to its ongoing regulatory interactions and any additional clinical work required to support an eventual U.S. approval.

---

2. Competitive Landscape

                  Broad-Spectrum IV Opioid Analgesics
                              │
              Generic IV morphine, fentanyl, hydromorphone
              (established, low-cost hospital standards)  ●
                              │
   ───────────────────────────┼───────────────────────────
     Differentiated/Non-Traditional Opioid Profile
                              │
                    Avenue Therapeutics ●
                 (IV tramadol — atypical, dual-mechanism
                  opioid/non-opioid analgesic profile)

Competitors

• Generic IV opioid analgesics (morphine, fentanyl, hydromorphone): The low-cost, well-established standard-of-care options in hospital acute post-operative pain management that Avenue's IV tramadol would need to differentiate against, largely on the basis of tramadol's comparatively lower abuse-liability and respiratory depression profile relative to traditional full-agonist opioids.
• Other acute pain management drug developers: A broader competitive field of pharmaceutical companies pursuing non-opioid or reduced-abuse-liability alternatives for post-surgical pain, reflecting the industry-wide push (amid the opioid crisis) toward safer acute pain management options.

---

3. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Patent protection around Avenue's specific IV tramadol formulation and its use in acute post-operative pain settings.
• A capital-efficient development strategy that leverages tramadol's long clinical history rather than the higher cost and risk of a novel chemical entity.
• Positioning within the broader public health push toward pain management options with a different abuse/dependency risk profile than traditional full-agonist opioids.

Strategic Risks & Vulnerabilities

1. Regulatory uncertainty: The company's value depends heavily on successful FDA review outcomes, which carry inherent uncertainty, particularly for products in the closely scrutinized pain management/opioid-adjacent category. Mitigation: continued engagement with FDA and additional clinical data generation as needed to support approval.
2. Small company scale and capital dependency: As a small, majority-owned subsidiary of Fortress Biotech, Avenue depends on continued capital support (from Fortress or external capital markets) to fund its regulatory and commercialization path. Mitigation: the Fortress Biotech affiliate structure provides some shared resources and capital markets access.
3. Competitive and reimbursement dynamics in hospital pain management: Hospital formulary decisions favor low-cost generic options unless a clear clinical or safety differentiation is established. Mitigation: positioning around tramadol's differentiated abuse-liability profile relative to traditional opioids.

---

4. Financial Overview

---

5. Summary Conclusion

Avenue Therapeutics has pursued a capital-efficient specialty pharma strategy of reformulating a well-understood analgesic, tramadol, into an intravenous option for acute post-operative pain management in hospital settings — a niche need given tramadol's differentiated risk profile relative to traditional full-agonist opioids.

The central strategic question is regulatory execution: Avenue's path forward depends on successfully satisfying FDA requirements for approval of IV tramadol, securing adequate capital support (through Fortress Biotech or external sources) to complete that process, and ultimately proving sufficient clinical and economic differentiation to gain adoption in hospital pain management protocols dominated by low-cost generic opioid alternatives.